Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ZTS · NYSE · Pharmaceuticals
Zoetis (ZTS) · oqro.io/stocks/ZTS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Zoetis was filed in the last 90 days. The latest on record was on May 13, 2026.
Since 2013, Zoetis insiders reported 25 open-market purchases and 215 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2026.
No open-market sale by an insider of Zoetis (ZTS) was filed with the SEC in the last 90 days.
Yes. Members of Congress disclosed 14 trades in Zoetis (ZTS) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. Byron Donalds (FL19), Rep. Gilbert Ray Cisneros Jr. (CA31), Sen. Markwayne Mullin.
Zoetis's next results are expected on Feb 10, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$85.57+2.09 (+2.50%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
−27.6% (−$32.57) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $118.14 on Nov 18, 2025 to $85.57 on Nov 18, 2026 (−27.6%). Disclosed in this range: 5 insider trades, 0 pre-arranged insider sales, 13 Congress trades, and 161 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceuticals company based in Parsippany, New Jersey.
Last 12 months
−27.6%
Market value
$34.8B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 16.7M shares sold short (4.1% of shares outstanding), −4.5% vs the previous count, 4.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Zoetis: 1 fund opened or increased a position in the latest available 13F filings and 1 member of Congress disclosed purchases. 2 of 3 tracked groups show buying activity. Based on public disclosures; it does not say why, or what happens next. Our test of this pattern
Revenue
$2.39B
−1.3% vs the same quarter a year earlier
Free cash flow, last 12 months
$2.23B
This quarter $717M, a year earlier $798M
Net debt
$7.72B
Debt $9.05B, cash $1.33B, at Sep 30, 2026
Net income, last 12 months
$2.51B
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Revenue, fiscal 2025
$9.47B
+2.3% vs the year before
Net income, fiscal 2025
$2.67B
As reported in the annual filing
Shares outstanding
406M
As of Oct 30, 2026
In fiscal 2025 the company spent $3.23B buying back its own shares. Cash actually paid, from its cash-flow statement.
Last dividend: $0.53 a share (quarterly), ex-date Oct 30, 2026, payable Dec 1, 2026. Calendar
New federal contracts from the last 12 months add up to 0.01% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Traded Oct 2, 2026 · disclosed 45 days later
Oct 2, 2026$1,001–$15,000Spouse
DetailsOfficial recordOct 2, 2026$1,001–$15,000
DetailsOfficial recordFund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Congress
Traded Sep 18 · disclosed 24 days later
Since the trade +19.9% · S&P 500 −4.1% · to Nov 18
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Zoetis reported 25 open-market purchases and 215 sales since 2013; purchases in 6 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $886K3×3 trades | $2.54M2×2 trades |
| 2025 | — | $483K5×5 trades |
| 2024 | — | $4.55M9×9 trades |
| 2023 | — | $13.3M17×17 trades |
| 2022 | — | $13.4M14×14 trades |
| 2021 | $1.25M3×3 trades | $64.5M43×43 trades |
| 2020 | — | $108M51×51 trades |
| 2019 | — | $71M40×40 trades |
| 2018 | $7461×1 trade | $58.7M25×25 trades |
| 2017 | — | $348K1×1 trade |
| 2016 | $103K2×2 trades | $788M6×6 trades |
| 2015 | $74.3M1×1 trade | $74.3M1×1 trade |
| 2013 | $1.33M15×15 trades | —1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by software from the filings listed below · Oct 26, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up freeOn the public record for Zoetis over the 12 months to Nov 19, 2026: 1 securities case.
Top officer leaving
“Departure of Wetteny Joseph, Executive Vice President and Chief Financial Officer On July 31, 2026, the Company entered into a letter agreement (the “Letter Agreement”) with Wetteny Joseph setting forth the terms of his departure from the Company.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
A securities lawsuit naming the company as a defendant was filed on May 27, 2026 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., 1:26-cv-04401Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). Coverage of court records is not complete, and shareholder derivative suits are not included.
People read Zoetis's Wikipedia article about 76 times a day over the last week, close to the 88 on a usual day of the three months before.
May 14, 2026Busiest day: 280 views on Jul 14, 2026Nov 18, 2026
Views of the article Zoetis, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
31 certified in FY2026 Q3, vs 56 a year earlier. 31 positions in total, median offered wage $105K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Authorization of Emergency Use for Four Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
Notice · Food and Drug Administration
Authorization of Emergency Use for Three Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
Notice · Food and Drug Administration
New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor; Change of Sponsor Address
Final rule · Food and Drug Administration
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 10, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Zoetis's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Zoetis's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Latest annual report filed Feb 12, 2026, compared with the one filed Feb 13, 2025. Read the filing
We are from time to time subject to claims and litigation arising in the ordinary course of business. These claims and litigation may include, among other things, allegations of violation of U.S. and foreign competition law, labor laws, consumer protection laws, and environmental laws and regulations, as well as claims or litigation relating to product liability, intellectual property, securities, breach of contract and tort. We operate in multiple jurisdictions and, as a result, a claim in one jurisdiction may lead to claims or regulatory penalties in other jurisdictions.
Source: SEC EDGAR, Form 10-K filed Feb 12, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Short sale volume: 38.6% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 42.9%. FINRA daily files, to Nov 18, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Off-exchange trading: 44.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (22.4% on ATS, 21.9% with other brokers), close to its 26-week average of 45.3%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: UBS ATS (12.0%), INTELLIGENT CROSS LLC (11.7%), SIGMA X2 (9.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Attention
Things to keep in mind
Against the S&P 500 over the year
Since Nov 17, 2025, ZTS is down 28.0% and the index fund is up 9.7%: 38 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ZTS moves
Beta 0.6 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).